| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a16bc330d87bb88689d1bdfed3551edf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-545 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 |
| filingDate |
1993-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_030393ca42bf9bca836b13c0d9e47e23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f133d796dbcdbc5c818fd959b66a79b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_241b5b829bca920e7f5d66c6739ff71d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cc26136e3d772636c5a2561d3d7c09f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cac4acd093baa186208c5edb5ffb0ed5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69b85d6ce5a41f07865cb9a80840c7c9 |
| publicationDate |
1995-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0647238-A1 |
| titleOfInvention |
INTERLEUKIN-1$g(b) DELETION MUTANT |
| abstract |
An Interleukin-1β deletion mutant, which has a quasi conserved sequence of three amino acids deleted from the amino acid sequence of an endogenous mammalian Interleukin-1β is disclosed. The deletion is Ser Asn Asp (numbers 52-54 of mature human IL-1β) in the case of human, mouse, rat and rabbit, and Arg Asp Asn in the case of bovine and sheep Interleukin-1β. The Interleukin-1β deletion mutant is shown to be an Interleukin-1 receptor ligand which binds to both Interleukin-1 type I receptors and Interleukin-1 type II receptors with substantially different binding-affinities. The ligand may have additional amino acid deletion(s) and/or point mutation(s). The Interleukin-1β deletion mutants may be used as carriers and adjuvants for biologically active molecules as well as in therapeutic and/or prophylactic agent. |
| priorityDate |
1992-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |